Cost-Consequence Analysis of Sacubitril/Valsartan versus Enalapril in Chronic Heart Failure Patients with Reduced Ejection Fraction

Cost-Consequence Analysis of Sacubitril/Valsartan versus Enalapril in Chronic Heart Failure Patients with Reduced Ejection Fraction

Purpose: The rising prevalence of heart failure (HF) in midlife years in Indians is posing an economic challenge. Sacubitril/valsartan demonstrated a significant risk reduction of cardiovascular deaths by 20% and HF rehospitalizations by 21% versus enalapril but has a higher drug cost. High cost is...

Full description

Bibliographic Details
Main Authors: Sameer Bhaskar GOKHALE, Saumitra RAY, Vijay Kumar CHOPRA, Uday JADHAV, Gauri BILLA
Format: Article
Language:English
Published: Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca 2021-07-01
Series:Applied Medical Informatics
Subjects:
enalapril
costs and cost analysis (cca)
heart failure
medical economics
sacubitril/valsartan
Online Access:https://ami.info.umfcluj.ro/index.php/AMI/article/view/811

Internet

https://ami.info.umfcluj.ro/index.php/AMI/article/view/811

Similar Items